New production facility for APIs to be built in Russia

16 February 2018

Active component, one of the largest producers of active pharmaceutical ingredients (APIs) in Russia, plans to increase its production by three times through the investing 2 billion roubles ($34 million) in the building a new facility, that will be located in the city of Pushkino of the St Petersburg region, reports The Pharma Letter’s local correspondent.

Alexander Semenov, president of Active component, said the majority of funds for the project will be provided by Russian banks in the form of loans.

Currently the company produces 35-40 tons of APIs per year. The start of production is scheduled for 2019-2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK